Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study

Table 2 Change in paired scores of irritable bowel syndrome symptoms after week 4 of GASTRAP^® DIRECT treatment (visit 1 to visit 3)

IBS symptoms	V1, mean ± SEM	V3, mean ± SEM	Responders, ∆ > 30%, n [% (95%CI)]	Paired decrease, mean ± SE (%)
Abdominal pain (0–10)	5.8 ± 2.4	2.9 ± 2.0c	64/96 [67 (57; 75)]	-2.9 ± 0.3 (50)
Bloating (0–10)	8.0 ± 1.7	4.7 ± 2.9c	58/96 [60 (50; 70)]	-3.2 ± 0.3 (40)
Abdominal distension (0–10)	7.2 ± 2.1	4.4 ± 3.1c	51/96 [53 (43; 63)]	-2.8 ± 0.4 (39)
Impact of global symptoms on daily life	7.1 ± 2.0	4.6 ± 2.9c	51/94 [54 (44; 64)]	-2.5 ± 0.3 (35)

^cP < 0.001.

95%CI: Confidence interval of the responder rate (Wilson method); IBS: Irritable bowel syndrome; V: Visit.